[A24-129] Tislelizumab (oesophageal squamous cell carcinoma, first line) – Benefit assessment according to §35a Social Code Book V
Last updated 18.06.2025
Project no.:
A24-129
Commission:
Commission awarded on 20.12.2024 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adults with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma that is not treatable with curative intent, whose tumours express PD-L1 with a Tumour Area Positivity score ≥ 5%
- Patients with tumour cell PD-L1 expression ≥ 1% or a combined positive score (CPS) ≥ 10; first-line treatment: added benefit not proven
- Patients with no tumour cell PD-L1 expression ≥ 1% and no CPS ≥ 10; first-line treatment: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
The current version 1.1 of the Dossier assessment replaces version 1.0 published on 01.04.2025.
https://doi.org/10.60584/A24-129_V1.1_en